Company

PolyNovo Limited

Headquarters: Port Melbourne, VIC, Australia

Employees: 122

CEO: Mr. R. Max Johnston

ASX: PNV -1.97%

Market Cap

A$1.64 Billion

AUD as of July 1, 2024

US$1.09 Billion

Market Cap History

PolyNovo Limited market capitalization over time

Evolution of PolyNovo Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of PolyNovo Limited

Detailed Description

Polynovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

PolyNovo Limited has the following listings and related stock indices.


Stock: ASX: PNV wb_incandescent

Details

Headquarters:

320 Lorimer Street

Unit 2

Port Melbourne, VIC 3207

Australia

Phone: 61 3 8681 4050

Fax: 61 3 8681 4099